81 FR 36314 - National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 81, Issue 108 (June 6, 2016)
National Institutes of Health
Federal Register Volume 81, Issue 108 (June 6, 2016)
| Page Range | 36314-36314 | |
| FR Document | 2016-13200 |
[Federal Register Volume 81, Number 108 (Monday, June 6, 2016)] [Notices] [Page 36314] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-13200] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Arthritis and Musculoskeletal and Skin Diseases Initial Review Group; Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee. Date: June 16-17, 2016. Time: 7:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Rd., Bethesda, MD 20852. Contact Person: Helen Lin, Ph.D., Scientific Review Officer, NIH/NIAMS/RB, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda, MD 20817, 301-594-4952, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS) Dated: May 27, 2016. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016-13200 Filed 6-3-16; 8:45 am] BILLING CODE 4140-01-P
![36314 Federal Register / Vol. 81, No. 108 / Monday, June 6, 2016 / Notices
Instructions: All submissions received Biologics Evaluation and Research, The meeting will be closed to the
must include the Docket No. FDA– Food and Drug Administration, 10903 public in accordance with the
2016–D–0643 for ‘‘Labeling for New Hampshire Ave., Bldg. 71, Rm. provisions set forth in sections
Biosimilar Products; Draft Guidance for 3128, Silver Spring, MD 20993–0002. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Industry; Availability.’’ Received Send one self-addressed adhesive label as amended. The grant applications and
comments will be placed in the docket to assist that office in processing your the discussions could disclose
and, except for those submitted as requests. See the SUPPLEMENTARY confidential trade secrets or commercial
‘‘Confidential Submissions,’’ publicly INFORMATION section for electronic property such as patentable material,
viewable at http://www.regulations.gov access to the draft guidance document. and personal information concerning
or at the Division of Dockets FOR FURTHER INFORMATION CONTACT: individuals associated with the grant
Management between 9 a.m. and 4 p.m., Sandra Benton, Center for Drug applications, the disclosure of which
Monday through Friday. Evaluation and Research, Food and would constitute a clearly unwarranted
• Confidential Submissions—To Drug Administration, 10903 New invasion of personal privacy.
submit a comment with confidential Name of Committee: Arthritis and
Hampshire Ave., Bldg. 51, Rm. 6340,
information that you do not wish to be Musculoskeletal and Skin Diseases Initial
Silver Spring, MD 20993–0002, 301–
made publicly available, submit your Review Group; Arthritis and Musculoskeletal
796–1042; or Stephen Ripley, Center for
comments only as a written/paper and Skin Diseases Special Grants Review
Biologics Evaluation and Research, Committee.
submission. You should submit two
Food and Drug Administration, 10903 Date: June 16–17, 2016.
copies total. One copy will include the
New Hampshire Ave., Bldg. 71, Rm. Time: 7:00 p.m. to 5:00 p.m.
information you claim to be confidential
7301, Silver Spring, MD 20993–0002, Agenda: To review and evaluate grant
with a heading or cover note that states
240–402–7911. applications.
‘‘THIS DOCUMENT CONTAINS Place: Bethesda North Marriott Hotel &
CONFIDENTIAL INFORMATION.’’ The SUPPLEMENTARY INFORMATION:
Conference Center, 5701 Marinelli Rd.,
Agency will review this copy, including I. Background Bethesda, MD 20852.
the claimed confidential information, in Contact Person: Helen Lin, Ph.D.,
its consideration of comments. The In the Federal Register of April 4, Scientific Review Officer, NIH/NIAMS/RB,
second copy, which will have the 2016 (81 FR 19194), FDA published a 6701 Democracy Blvd., Suite 800, Plaza One,
claimed confidential information notice with a 60-day comment period to Bethesda, MD 20817, 301–594–4952, linh1@
request comments on the draft guidance mail.nih.gov.
redacted/blacked out, will be available
for public viewing and posted on http:// for industry entitled ‘‘Labeling for (Catalogue of Federal Domestic Assistance
Biosimilar Products.’’ FDA is extending Program Nos. 93.846, Arthritis,
www.regulations.gov. Submit both
the comment period for an additional 60 Musculoskeletal and Skin Diseases Research,
copies to the Division of Dockets National Institutes of Health, HHS)
Management. If you do not wish your days, until August 2, 2016. The Agency
name and contact information to be believes that a 60-day extension will Dated: May 27, 2016.
made publicly available, you can allow adequate time for interested Sylvia L. Neal,
provide this information on the cover persons to submit comments without Program Analyst, Office of Federal Advisory
sheet and not in the body of your compromising timely publication of the Committee Policy.
comments and you must identify this final guidance. [FR Doc. 2016–13200 Filed 6–3–16; 8:45 am]
information as ‘‘confidential.’’ Any II. Electronic Access
BILLING CODE 4140–01–P
information marked as ‘‘confidential’’
will not be disclosed except in Persons with access to the Internet
accordance with 21 CFR 10.20 and other may obtain the draft guidance at http:// DEPARTMENT OF HEALTH AND
applicable disclosure law. For more www.fda.gov/Drugs/Guidance HUMAN SERVICES
information about FDA’s posting of ComplianceRegulatoryInformation/
comments to public dockets, see 80 FR Guidances/default.htm, http:// National Institutes of Health
56469, September 18, 2015, or access www.fda.gov/BiologicsBloodVaccines/ Center for Scientific Review; Notice of
the information at: http://www.fda.gov/ GuidanceComplianceRegulatory Closed Meetings
regulatoryinformation/dockets/ Information/Guidances/default.htm, or
default.htm. http://www.regulations.gov. Pursuant to section 10(d) of the
Docket: For access to the docket to Dated: May 31, 2016. Federal Advisory Committee Act, as
read background documents or the amended (5 U.S.C. App.), notice is
Leslie Kux,
electronic and written/paper comments hereby given of the following meetings.
Associate Commissioner for Policy. The meetings will be closed to the
received, go to http://
www.regulations.gov and insert the [FR Doc. 2016–13223 Filed 6–3–16; 8:45 am] public in accordance with the
docket number, found in brackets in the BILLING CODE 4164–01–P provisions set forth in sections
heading of this document, into the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
‘‘Search’’ box and follow the prompts as amended. The grant applications and
and/or go to the Division of Dockets DEPARTMENT OF HEALTH AND the discussions could disclose
Management, 5630 Fishers Lane, Rm. HUMAN SERVICES confidential trade secrets or commercial
1061, Rockville, MD 20852. property such as patentable material,
Submit written requests for single National Institutes of Health
and personal information concerning
copies of the draft guidance to the individuals associated with the grant
sradovich on DSK3TPTVN1PROD with NOTICES
National Institute of Arthritis and
Division of Drug Information, Center for Musculoskeletal and Skin Diseases; applications, the disclosure of which
Drug Evaluation and Research, Food Notice of Closed Meeting would constitute a clearly unwarranted
and Drug Administration, 10001 New invasion of personal privacy.
Hampshire Ave., Hillandale Building, Pursuant to section 10(d) of the Name of Committee: Center for Scientific
4th Floor, Silver Spring, MD 20993– Federal Advisory Committee Act, as Review Special Emphasis Panel; Member
0002; or the Office of Communication, amended (5 U.S.C. App.), notice is Conflicts and Continuous Submission:
Outreach and Development, Center for hereby given of the following meeting. Ischemia and HDL.
VerDate Sep<11>2014 16:36 Jun 03, 2016 Jkt 238001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\06JNN1.SGM 06JNN1](https://thefederalregister.org/doc/81_FR_36422/page/1.svg)
Document Created: 2016-06-04 00:16:49
Document Modified: 2016-06-04 00:16:49
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | June 16-17, 2016. | |
| FR Citation | 81 FR 36314 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR